Skip to main content
TELO
NASDAQ Life Sciences

Telomir-1 Shows Significant Efficacy in Preclinical Triple-Negative Breast Cancer Models

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.4
Mkt Cap
$46.071M
52W Low
$1.12
52W High
$5.4
52W Position info
25% above low
Off High info
74% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

TELO sits 25% above its 52-week low of $1.12 on light trading volume (0.2× avg).

Summary

Telomir Pharmaceuticals announced positive preclinical results for Telomir-1, demonstrating significant reductions in tumor growth and metastasis in aggressive triple-negative breast cancer animal models.


Key Events · Product Development and Regulatory · TELO

  • Positive Preclinical Efficacy

    Telomir-1 significantly reduced primary tumor growth and metastasis in two aggressive triple-negative breast cancer (TNBC) animal models.

  • Efficacy in Aggressive TNBC

    Telomir-1 demonstrated statistically significant reductions in tumor growth in models representing 40-60% of TNBC cases, both as monotherapy and in combination with chemotherapy.

  • Guidance for Clinical Development

    The study results provide important guidance for patient selection and future clinical trial design, informing ongoing IND-enabling activities.


Analysis · TELO · Life Sciences

This 8-K reports encouraging preclinical data for Telomir-1 in triple-negative breast cancer (TNBC), a challenging cancer with limited treatment options. The statistically significant reductions in tumor growth and metastasis in two aggressive TNBC models suggest potential efficacy for a substantial portion of TNBC patients. These findings provide crucial guidance for the company's IND-enabling activities and future clinical trial design, de-risking the development path for this lead candidate. For a small life sciences company, positive preclinical data for a serious indication can be a significant catalyst.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TELO was trading at $1.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46.1M. The 52-week trading range was $1.12 to $5.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TELO - Latest Insights

TELO
Nov 06, 2026, 4:41 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.740
Real-time Price: $0.4659 info
Change: -$0.2741 (-37%) info
Market Cap: $32.403M info
TELO
Oct 27, 2026, 4:30 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.02
Real-time Price: $0.4659 info
Change: -$0.5541 (-54%) info
Market Cap: $32.403M info
TELO
Oct 06, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.24
Real-time Price: $0.4659 info
Change: -$0.7741 (-62%) info
Market Cap: $32.403M info
TELO
Oct 06, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.28
Real-time Price: $0.4659 info
Change: -$0.8141 (-64%) info
Market Cap: $32.403M info
TELO
Aug 13, 2026, 5:10 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.05
Real-time Price: $0.4659 info
Change: -$0.5841 (-56%) info
Market Cap: $32.403M info